Cullgen Announces Conference Participation During J.P. Morgan Healthcare Conference Week
- Updated corporate presentation posted to website -
SAN DIEGO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Cullgen Inc. (“Cullgen”), a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader therapies, today announced its attendance at conferences during the week of the 44th Annual J.P. Morgan Healthcare Conference (“JPM week”) including at LifeSci Advisors' Corporate Access Event and the Demy-Colton/Informa Biotech Showcase™.
Information on both events is below.
LifeSci Advisors 15th Annual Corporate Access Event
Date: January 14, 2026
Format: One-on-one meetings
Location: The Beacon Grand, San Francisco, CA
Demy-Colton/Informa Biotech Showcase
Dates: January 12-13, 2026
Format: One-on-one meetings
Location: Hilton San Francisco Union Square, San Francisco, CA
To request an in-person meeting with the Cullgen management team on Wednesday January 14th, either register at LifeSci Partners Corporate Access Event 2026 or contact our LifeSci Partners representative Alex Grossman (alex@lifesciadvisors.com). Registered participants of the Biotech Showcase can request an in-person meeting on Monday January 12 or Tuesday January 13 with Cullgen’s SVP of Corporate Development, Seth Goldblum, by using the Biotech Showcase partnering system.
Updated Corporate Presentation
In addition, Cullgen announced that it has posted an updated corporate presentation to its website which can be found at https://www.cullgen.com/about-us. Among other updates, this presentation includes more details on Cullgen’s TRK degrader for pain program which is anticipated to begin Phase 2 clinical trials during Q2 2026, progress on Cullgen’s degrader-antibody conjugates (DACs) programs, and an updated pipeline that now includes a new targeted protein degrader program that has advanced into IND-enabling studies for the treatment of inflammatory diseases.
About Cullgen Inc.
Cullgen is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader therapies designed to improve the lives of patients suffering from critical conditions such as pain, cancer and inflammatory diseases. Cullgen has created a portfolio of highly selective targeted protein degrader product candidates designed to potently and efficiently eliminate therapeutically relevant proteins in patients. By leveraging its expertise in targeted protein degraders, Cullgen believes its product candidates have many distinct advantages over other therapeutic modalities, including higher selectivity, improved therapeutic profile and avoidance of known toxicities.
Cullgen’s lead product candidate, CG001419, is an oral pan-tropomyosin receptor kinase (“TRK”) degrader that recently completed a Phase 1 trial for the treatment of acute post-operative pain. The molecule is also being studied in a Phase 1 trial for the treatment of solid tumors. Cullgen’s second product candidate, CG009301, is a GSPT1 degrader being studied in a Phase 1 trial for the treatment of blood cancers, including relapsed/refractory acute myeloid leukemia, higher-risk myelodysplastic syndrome and acute lymphoblastic leukemia. In addition to CG001419 and CG009301, Cullgen is also progressing a number of preclinical programs including next-generation degrader-antibody conjugates.
For more information, please visit www.cullgen.com.
Forward-Looking Statements
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements include, but are not limited to, statements not purely of historical fact and may be identified by words such as "anticipates," "assumes," "believes," "can," "could," "estimates," "expects," "forecasts," "guides," "intends," "is confident that", "may," "plans," "seeks," "projects," "targets," and "would," and their opposites and similar expressions are intended to identify forward-looking statements. These forward-looking statements include express or implied statements relating to: the therapeutic potential and utility, efficacy and clinical benefits of CG001419, including for the treatment of pain and solid tumors; the risk/benefit profile of CG001419, including the potential of CG001419 to reduce the risk of addiction associated with other pharmaceutical therapies for the treatment of pain; expectations regarding Cullgen’s research and development efforts, including timing of Cullgen’s anticipated IND filing with the FDA and initiation of Phase 2 trials for CG001419; Cullgen’s expectations regarding the advancement of product candidates into IND-enabling studies; and Cullgen’s expectations, hopes, beliefs, intentions and strategies; and other statements that are not historical fact. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to: risks associated with the Cullgen’s ability to manage expenses and unanticipated spending and costs that could reduce Cullgen’s cash resources; risks related to the Cullgen’s ability to correctly estimate its operating expenses and other events; changes in capital resource requirements; risks related to the inability of the Cullgen to obtain sufficient additional capital to continue to advance its product candidates, its preclinical programs and its clinical trials; the ability of the Cullgen to obtain, maintain and protect its intellectual property rights, in particular those related to its product candidates; Cullgen’s ability to advance the development of its product candidates or preclinical activities under the timelines it anticipates in planned and future clinical trials; Cullgen’s ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; Cullgen’s ability to realize the anticipated benefits of its research and development programs, strategic partnerships, licensing programs or other collaborations; regulatory requirements or developments and Cullgen’s ability to obtain necessary approvals from the U.S. Food and Drug Administration or other regulatory authorities; changes to clinical trial designs and regulatory pathways; changes in expected or existing competition; and legislative, regulatory, political and economic developments. A discussion of these and other factors, including risks and uncertainties with respect to Cullgen, is set forth in Pulmatrix Inc.’s (“Pulmatrix”) definitive proxy statement/prospectus filed with the Securities and Exchange Commission and declared effective on May 9, 2025, as may be supplemented or amended by Pulmatrix’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as risk factors associated with companies, such as Cullgen, that operate in the biopharma industry. Should one or more of these risks or uncertainties materialize, or, should any of Cullgen’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Cullgen does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in Pulmatrix or Cullgen.
CONTACTS:
Cullgen Inc.
Thomas Eastling, CFO
Investors
Chuck Padala
Managing Director, LifeSci Advisors
chuck@lifesciadvisors.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
